文献速递细菌感染、耐药与抗菌药物

磷霉素在多重耐药大肠埃希菌所致菌血症性尿路感染非危重患者中的群体药代动力学与药效学

Population pharmacokinetics and pharmacodynamics of fosfomycin in non-critically ill patients with bacteremic urinary infection caused by multidrug-resistant Escherichia coli.
PubMed 文献 · Clin Microbiol Infect · 2018-04-10

基于FOREST临床试验中16例多重耐药大肠埃希菌菌血症性尿路感染患者,接受静脉磷霉素4 g每6小时治疗,分析群体药代动力学并进行蒙特卡洛模拟。磷霉素浓度变异大,部分由肾功能不全解释;增加剂量至8 g每8小时仅轻度改善药效靶标达成,且均无法达到抑制耐药靶标。作者支持4 g每6小时作为有效方案,并提示需重新评估药敏折点。

要点

  • 磷霉素浓度高度变异,部分可由肾功能不全解释。
  • 4 g每6小时与8 g每8小时在EUCAST折点下1-log菌量下降达标率89%–96%,CLSI折点下33%–54%。
  • 两种剂量均无法达到抑制细菌耐药靶标,作者支持4 g每6小时用于非危重患者。

核心结论

  • 磷霉素浓度高度变异,部分由肾功能不全解释;本研究支持4 g每6小时作为多重耐药大肠埃希菌菌血症性尿路感染非危重患者的有效方案,更高剂量可能增加毒性但未必显著提高疗效。
  • 现有信息可能提示磷霉素药敏折点需要重新评估。

研究设计与样本

  • 分析FOREST临床试验中16例多重耐药大肠埃希菌菌血症性尿路感染患者,接受静脉磷霉素4 g每6小时治疗,进行群体药代动力学分析及蒙特卡洛模拟(4 g每6小时与8 g每8小时)。

主要发现

  • 在开始磷霉素治疗后第2或3天的一个给药间期内共采集64份血浆样本,磷霉素浓度高度变异。
  • 药效靶标达成分析显示,增加磷霉素剂量(4 g每6小时 vs 8 g每8小时)仅轻度改善达标率。
  • 这些剂量在EUCAST折点下使89%至96%的患者达到1-log细菌负荷下降,在CLSI折点下为33%至54%,但均无法达到抑制细菌耐药靶标。

关键数值与推荐

  • 药效靶标包括大肠埃希菌的静态效应、1-log细菌负荷下降和耐药抑制。
  • 1-log细菌负荷下降达标率:EUCAST折点下89%至96%,CLSI折点下33%至54%。

临床怎么用

  • 作者支持使用4 g每6小时作为多重耐药大肠埃希菌所致菌血症性尿路感染非危重患者的有效治疗方案。
  • 作者认为更高剂量可能增加毒性但未必显著提高疗效。
  • 作者提示现有信息可能表明磷霉素药敏折点需要重新评估。

局限性

  • 磷霉素浓度高度变异,部分由肾功能不全解释。
  • 这些剂量无法达到抑制细菌耐药靶标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To describe the population pharmacokinetics of fosfomycin for patients with bacteraemic urinary tract infection (BUTI). The analysis identified optimal regimens on the basis of pharmacodynamic targets and assessed the adequacy of Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) susceptibility breakpoints for Escherichia coli. METHODS: Data of 16 patients with BUTI caused by multidrug-resistant E. coli (FOREST clinical trial) received intravenous fosfomycin (4 g every 6 hours) were analysed. A population pharmacokinetic analysis was performed, and Monte Carlo simulations were undertaken using 4 g every 6 hours and 8 g every 8 hours. The probability of pharmacodynamic target attainment was assessed using pharmacodynamic targets for E. coli for static effect, 1-log drop in bacterial burden and resistance suppression. RESULTS: Sixty-four plasma samples were collected over a single dosing interval (day 2 or 3 after starting fosfomycin treatment). Fosfomycin concentrations were highly variable. Pharmacodynamic target attainment analysis showed mild improvement by increasing fosfomycin dosing (4 g every 6 hours vs. every 8 hours). These dosages showed success for decreasing 1-log bacterial burden in 89% to 96% (EUCAST breakpoints) and 33% to 54% (CLSI breakpoints) of patients, but they were unable to reach bacterial resistance suppression targets. CONCLUSIONS: Fosfomycin concentrations are highly variable-a fact partially explained by renal impairment. The present work supports the use of 4 g every 6 hours as an effective regimen for the treatment of non-critically ill patients with BUTI caused by multidrug-resistant E. coli, as higher dosages might increase toxicity but may not significantly increase efficacy. The current information may suggest that fosfomycin susceptibility breakpoints need to be reappraised.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Merino-Bohórquez V, Docobo-Pérez F, Sojo J, et al. Population pharmacokinetics and pharmacodynamics of fosfomycin in non-critically ill patients with bacteremic urinary infection caused by multidrug-resistant Escherichia coli. Clin Microbiol Infect. 2018. PMID: 29649596. doi:10.1016/j.cmi.2018.02.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。